DOCSLIB.ORG

Pharm Exec We Leap Tall Buildings to Bring You the Definitive Guide to the World’S Top Pharma Companies 50 by PHARM EXEC STAFF MAY 2009 69

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Pharm Exec We Leap Tall Buildings to Bring You the Definitive Guide to the World’S Top Pharma Companies 50 by PHARM EXEC STAFF MAY 2009 69 68 PHARMACEUTICAL EXECUTIVE the Pharm Exec We leap tall buildings to bring you the definitive guide to the world’s top pharma companies 50 BY PHARM EXEC STAFF MAY 2009 www.pharmexec.com 69 THE PHARM EXEC 50 1. Pfizer 2. GlaxoSmithKline 3. Sanofi-Aventis he Pharm Exec 50—the world’s over-the-counter drug revenue. For- 4. Novartis top 50 pharmaceutical compa- eign currencies are converted using the 5. AstraZeneca nies—accounted for prescrip- interbank rate for the last day of the 6. Johnson & Johnson tion drug sales of $558 billion company’s fiscal year—December 31, 7. Merck Tin 2008. Though a few more compa- 2008, for most European companies 8. Roche nies dipped into negative growth than and March 31, 2008, for most Japa- 9. Eli Lilly last year, more than half of the list nese companies. This year, we made 10. Wyeth achieved double-digit growth, a sign one exception to this policy: GlaxoS- 11. Bristol-Myers Squibb that although recession eventually mithKline, the only company among 12. Abbott We leap tall buildings hits even pharma, it usually hits later the 50 to report its revenue in Brit- 13. Bayer to bring you the than in many other industries. ish pounds. At the end of 2008, the 14. Amgen Our rankings are based on compa- pound dipped to record lows against 15. Schering-Plough definitive guide to nies’ own reported sales, taken from the dollar. At those rates, the com- 16. Boehringer Ingelheim SEC filings and annual reports. In a pany would have fallen to fifth place 17. Takeda the world’s top handful of cases—mostly involving in the rankings, posting a revenue loss 18. Teva private companies that do not dis- of more than 20 percent. Because that 19. Genentech pharma companies close sales figures—we have relied seemed a distortion of GSK’s perfor- 20. Astellas on sales figures graciously provided mance, we converted the company’s BY PHARM EXEC STAFF 21. Daiichi Sankyo by IMS Health. (These numbers are sales figures as if the fiscal year ended 22. Novo Nordisk marked by an asterisk in the rank- in April 2009. This may slightly over- 23. Merck KGaA ings chart.) Though IMS numbers state GSK’s performance, but it seems 24. Eisai typically vary somewhat from the fig- to better reflect reality. ures reported to the SEC, we feel they Next year’s list will of course be 25. Otsuka are close enough to give a fair sense much different, thanks to the round 26. Baxter of how the non-reporting companies of mergers announced since the begin- 27. Servier compare with their peers. ning of the year. For a preview of how 28. Gilead Sciences Our sales figures reflect global the Top Ten will change, we offer a 29. Mylan sales of human prescription drugs and “what if” version of the Top Ten—re- 30. UCB vaccines. As far as possible, we have calculating 2008 revenue of the Top 31. Genzyme excluded royalty revenue, contract Ten as if the mergers took place last 32. Solvay manufacturing, animal health, and year—on page 76. 33. Ratiopharm 34. Mitsubishi Tanabe 35. Chugai CHARACTER (OPPOSITE) CREATED AND ILLUSTRATED BY CRAIG FOSTER 36. Allergan 37. Forest 38. CSL 39. Procter & Gamble 40. Nycomed 41. Menarini 42. Biogen Idec 43. Shire 44. Alcon 45. Lundbeck 46. Dainippon Sumitomo 47. Cephalon 48. Hospira 49. Watson 50. Actavis 70 PHARMACEUTICAL EXECUTIVE50 Rank Company & Headquarters 2008 Global Pharma R&D Spend 2008 Top-Selling Drugs [‘07 Rank] [Web site] Sales [change from 2007] [2008 sales] Pfizer Lipitor [$12.4 B] [1] $44.2 B [-0.5%] $7.9 B Lyrica [$2.6 B] 1 New York, NY [pfizer.com] Celebrex [$2.5 B] GlaxoSmithKline Seretide/Advair [$6.0 B] [2] $43.0 B [11.2%] $5.2 B Valtrex [$1.7 B] 2 Brentford, England [gsk.com] Lamictal [$1.4 B] Sanofi-Aventis Lovenox [$3.9 B] [3] $38.7 B [4.8%] $6.5 B Plavix [$3.7 B] 3 Paris, France [sanofi-aventis.com] Lantus [$3.5 B] Novartis Diovan/Co-Diovan [$5.7 B] [4] $36.0 B [10.7%] $7.2 B Gleevec/Glivec [$3.7 B] 4 Basel, Switzerland [novartis.com] Zometa [$1.4 B] AstraZeneca Nexium [$5.2 B] [5] $31.6 B [10.1%] $5.1 B Seroquel [$4.5 B] 5 London, England [astrazeneca.com] Crestor [$3.6 B] Johnson & Johnson Remicade [$3.7 B] [6] $24.6 B [-1.2%] $5.1 B Topamax [$2.7 B] 6 New Brunswick, NJ [jnj.com] Procrit [$2.5 B] Merck Singulair [$4.4 B] [7] $23.6 B [-2.4%] $4.8 B Cozaar/Hyzaar [$3.6 B] 7 Whitehouse Station, NJ [merck.com] Fosamax [$1.6 B] Roche MabThera/Rituxan [$5.6 B] [8] $21.0 B [3.4%] $7.2 B Avastin [$4.9 B] 8 Basel, Switzerland [roche.com] Herceptin [$4.8 B] Eli Lilly Zyprexa [$4.7 B] [10] $19.3 B [9.6%] $3.8 B Cymbalta [$2.7 B] 9 Indianapolis, IN [lilly.com] Gemzar [$1.6 B] Wyeth Effexor [$3.9 B] [9] $19.0 B [2.3%] $3.4 B Prevnar [$2.7 B] 10 Madison, NJ [wyeth.com] Enbrel [$2.6 B] [The Top 10: The Year in Review] Pfizer: Acquired Coley for atrial fibrillation // Acquired projects in development, 10 in year’s top pharma industry stories Pharmaceutical Group, CovX Acambis, long-time vaccine Phase III Research, Encysive, and Serenex development partner of Sanofi Roche: Acquired Piramed, Mirus, // Toviaz approved in the US // Pasteur // Announced acquisition Johnson & Johnson: Launched and Arius // 12 Phase III programs By year’s end had 106 projects in of generics manufacturer Zentiva Zyrtec OTC // Acquired Omrix initiated // In July, announced development, including 84 NMEs Biopharmaceuticals, manufacturer intention to purchase shares of // Launched Pfizer Regenerative Novartis: 152 projects in clinical of biosurgical hemostats // In the Genentech it did not already own Medicine in Cambridge, UK, and development // Struck deal with consumer products arena, acquired Cambridge, MA // Completed Nestlé for multi-stage purchase of Beijing Dabao Cosmetics // Lilly: John Lechleiter replaced pivotal trial for Dimebon in majority stake in eye care specialist Received FDA approval of Nucynta Sidney taurel as CEO // Acquired Alzheimer’s Alcon // Reorganized and put immediate release tablets for ImClone Systems // New new leaders in charge of several moderate to severe acute pain indications approved for Alimta, GSK: Twelve product launches, divisions; Joerg Reinhardt became Cymbalta, Cialis, and others including US launches of Promacta, COO // Three submissions received Merck: Rolled out new Entereg, Rotarix, Boostrix, Kinrix accelerated US review commercial models in US and Wyeth: FDA approved Xyntha // Moved five candidates into other top markets // Filed SNDAs for hemophilia and Pristiq for Phase III // Created 35 Discovery AstraZeneca: JUPITER study for Isentress and Gardasil // depression // Biotech products Performance Units // Acquired RNAi demonstrated that Crestor cuts Launched restructuring, including hit 43 percent of total revenue // specialist Sirtris heart attack risk even in patients loss of 7,200 positions // The On January 26, 2009, announced with normal cholesterol // results of the ENHANCE trial, which plans to merge with Pfizer. Sanofi-Aventis: Submitted Cyltiri Successfully defended patents found that Vytorin did not reduce for sleep disorders, and Multaq of Seroquel and Nexium // 144 arterial plaque, became one of the MAY 2009 www.pharmexec.com 71 Rank Company & Headquarters 2008 Global Pharma R&D Spend 2008 Top-Selling Drugs [‘07 Rank] [Web site] Sales [change from 2007] [2008 sales] Bristol-Myers Squibb $17.7 B [13.6%] $3.6 B Plavix [$5.6 B] 11[11] New York, NY [bms.com] Abbott $16.7 B [14.4%] $2.7 B Humira [$4.5 B] 12[13] Abbott Park, IL [abbott.com] Bayer $15.1 B [0.6%] $2.5 B YAZ/ Yasmin/ Yasminelle [$1.7 B] 13[12] Leverkusen, Germany [bayer.com] Amgen $14.7 B [2.7%] $3.0 B Enbrel [$3.6 B] 14[14] Thousand Oaks, CA [amgen.com] Schering-Plough $14.2 B [39.7%] $3.5 B Remicade [$2.1 B] 15[16] Kenilworth, NJ [schering-plough.com] TOP 10 US PRODUCTS OF 2008 GLOBAL PHARMACEUTICAL SALES BY REGION, 2008 Product [Maker] 2008 Sales in billions Growth in Sales Percent of Global Sales Market 2008 Sales (US$B) % Growth from 2007 1. Lipitor [Pzer] $7.8 -3.7% North America $311.8 1.4% 2. Nexium [AstraZeneca] $5.9 7.2% Europe $247.5 5.8% 3. Plavix [Sano-Aventis/BMS] $4.9 25.6% Asia/Africa/Australia $90.8 15.3% 4. Advair Diskus [GlaxoSmithKline] $4.4 2.3% 32% Japan $76.6 2.1% 5. Seroquel [AstraZeneca] $3.9 11.4% 40.3% Latin America $46.5 12.6% 6. Singulair [Merck] $3.5 2.9% SOURCE: IMS Health Market Prognosis, March 2009 Plavix was 7. Enbrel [Amgen/Wyeth] $3.4 unchanged 11.8% 8. Neulasta [Amgen] $3.1 % unchanged 26 IMS Heatlh TOP 10 R&D SPEND 9. Actos [Takeda] $3.1 UPin 2008 6.9% 9.9% Company Total R&D Spend US billions 10. Epogen [Amgen] $3.1 unchanged SOURCE: 6% 1. Pzer $7.9 2. Roche $7.2 TOP 10 GLOBAL PRODUCTS OF 2008 The global pharmaceutical [24] 3. Novartis $7.2 Product [Maker] 2008 Sales in billions Growth in Sales market grew by 4. Sano-Aventis $6.5 1. Lipitor [Pzer] $13.7 -.9% NUMBER OF NEW 5. GSK $5.2 2. Plavix [Sano-Aventis/BMS] $8.6 16.9% 4.8 percent DRUGS APPROVED 6. AstraZeneca $5.1 3. Nexium [AstraZeneca] $7.8 7.8% to approximately BY FDA, UP FROM 7.
Load more

Recommended publications
  • Fully Human Domain Antibody Therapeutics: the Best of Both Worlds
    Drug Discovery Fully Human Domain Antibody Therapeutics: The Best of Both Worlds By combining the therapeutic benefits of small molecule drugs with those of fully human antibodies, Domain Antibodies are expected to have strong therapeutic and commercial potential. By Robert Connelly at Domantis Robert Connelly is Chief Executive Officer of Domantis. He has over 22 years’ commercial experience of the life science sector, including that gained in the fields of diagnostics, drug discovery technologies and antibody therapeutics. Prior to joining Domantis, he was CEO of Veritas Pharmaceuticals (Los Angeles, USA), an in vivo imaging start-up company. He spent over five years with IGEN International, latterly as Senior Vice President and General Manager, Life Sciences, where he took part in the company’s IPO and financing rounds, raising $130 million. The first 11 years of his career were spent at Abbott Laboratories in sales, marketing and management positions. Domain Antibodies (dAbs) are the smallest functional variable regions of either the heavy (VH) or light (VL) binding units of antibodies. At Domantis, we are chains of human antibodies. Domantis scientists applying our proprietary know-how in dAbs to deliver have used the variable domains sequences of human human therapies that address large, unmet medical antibodies to create a series of large and highly needs in areas such as inflammation, cancer and functional libraries of fully human dAbs, with each autoimmune diseases. Three and a half years after library comprising at least 1010 different dAbs. The opening our laboratories, we have a dozen proprietary dAbs selected from these libraries are both specific therapeutic programmes underway, and an additional for their biological target and are well folded and eight therapeutic programmes with partners.
    [Show full text]
  • XCHANGE COMMISSION Washington, D.C
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) (X) ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 1999 ( ) TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-19034 REGENERON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) New York 13-3444607 (State or other jurisdiction of (I.R.S. Employer Identification No) incorporation or organization) 777 Old Saw Mill River Road, Tarrytown, New York 10591-6707 (Address of principal executive offices) (Zip code) (914) 347-7000 (Registrant's telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: None (Title of Class) Securities registered pursuant to Section 12(g) of the Act: Common Stock - par value $.001 per share (Title of Class) Preferred Share Purchase Rights expiring October 18, 2006 (Title of Class) Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes /X/ No Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (ss. 229.405 of this chapter) is not contained herein, and will not be contained, to the best of registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.
    [Show full text]
  • Virginia: in the Circuit Court of Pittsylvania County
    VIRGINIA: IN THE CIRCUIT COURT OF PITTSYLVANIA COUNTY PITTSYLVANIA COUNTY, Plaintiff, v. PURDUE PHARMA, L.P.; PURDUE PHARMA, INC.; THE PURDUE FREDERICK COMPANY, INC.; RHODES PHARMACEUTICALS, L.P.; ABBOTT LABORATORIES; ABBOTT LABORATORIES, INC.; MALLINCKRODT PLC; MALLINCKRODT LLC; ENDO HEALTH SOLUTIONS, INC; ENDO PHARMACEUTICALS, INC.; PAR Case No. CL18 - __________ PHARMACEUTICAL COMPANIES, INC.; PAR PHARMACEUTICAL, INC.; TEVA Jury Trial Demanded PHARMACEUTICALS USA, INC.; CEPHALON, INC.; BARR LABORATORIES, INC.; JANSSEN PHARMACEUTICALS, INC.; ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC.; JANSSEN PHARMACEUTICA, INC.; WATSON LABORATORIES, INC.; ALLERGAN PLC; ACTAVIS PHARMA, INC.; ACTAVIS, LLC; INSYS THERAPEUTICS, INC.; KVK-TECH, INC.; AMNEAL PHARMACEUTICALS LLC; IMPAX LABORATORIES, LLC; AMNEAL PHARMACEUTICALS, INC.; AMNEAL PHARMACEUTICALS OF NEW YORK, LLC; MYLAN PHARMACEUTICALS, INC.; MCKESSON CORPORATION; MCKESSON MEDICAL-SURGICAL INC.; CARDINAL HEALTH, INC.; AMERISOURCEBERGEN DRUG CORPORATION; HENRY SCHEIN, INC.; GENERAL INJECTABLES & VACCINES, INC.; INSOURCE, INC.; CVS HEALTH CORPORATION; CVS PHARMACY, INC.; CVS TN DISTRIBUTION, L.L.C.; WALGREENS BOOTS ALLIANCE, INC.; WALGREEN CO.; EXPRESS SCRIPTS HOLDING COMPANY; EXPRESS SCRIPTS, INC; CAREMARK RX, L.L.C.; CAREMARKPCS HEALTH, L.L.C.; CAREMARK, L.L.C.; UNITEDHEALTH GROUP INCORPORATED; OPTUM, INC.; OPTUMRX, INC.; and DOES 1-100, Defendants. PLAINTIFF’S ORIGINAL COMPLAINT Plaintiff, Pittsylvania County, Virginia, by and through the undersigned attorneys, (hereinafter “Plaintiff,” “Pittsylvania
    [Show full text]
  • Surescripts, Llc As Amicus Curiae in Support of Petitioners in No
    Nos. 19-508 and 19-825 In the Supreme Court of the United States ———————————— AMG CAPITAL MANAGEMENT, LLC, ET AL., Petitioners, v. FEDERAL TRADE COMMISSION, Respondent. ———————————— FEDERAL TRADE COMMISSION, Petitioner, v. CREDIT BUREAU CENTER, LLC, ET AL., Respondents. ———————————— ON WRITS OF CERTIORARI TO THE UNITED STATES COURTS OF APPEALS FOR THE SEVENTH AND NINTH CIRCUITS ———————————— BRIEF OF SURESCRIPTS, LLC AS AMICUS CURIAE IN SUPPORT OF PETITIONERS IN NO. 19-508 AND RESPONDENTS IN NO. 19-825 ———————————— ALFRED C. PFEIFFER, JR. ROMAN MARTINEZ LATHAM & WATKINS LLP Counsel of Record 505 Montgomery Street AMANDA P. REEVES Suite 2000 ALLYSON M. MALTAS San Francisco, CA 94111 DOUGLAS C. TIFFT BLAKE E. STAFFORD JAMES A. TOMBERLIN* LATHAM & WATKINS LLP 555 Eleventh Street, NW Suite 1000 Washington, DC 20004 (202) 637-2200 [email protected] Counsel for Amicus Curiae Surescripts, LLC TABLE OF CONTENTS Page TABLE OF AUTHORITIES ...................................... ii INTEREST OF AMICUS CURIAE ............................1 SUMMARY OF ARGUMENT .....................................3 ARGUMENT ...............................................................5 I. The FTC Has Increasingly Wielded Section 13(b) To Obtain Monetary Relief In Antitrust Cases ................................................5 II. The FTC’s Antitrust Authority Confirms That Section 13(b) Does Not Authorize Monetary Relief ..................................................22 CONCLUSION ..........................................................32 ii TABLE OF AUTHORITIES Page(s) CASES Apple Inc. v. Pepper, 139 S. Ct. 1514 (2019) .......................................... 13 Armstrong v. Exceptional Child Center, Inc., 575 U.S. 320 (2015) .............................................. 23 Bell Atlantic Corp. v. Twombly, 550 U.S. 544 (2007) .............................................. 26 In re Cardinal Health, Inc., No. 101-0006, 2015 WL 1849040 (F.T.C. Apr. 17, 2015) ........................ 19, 20, 28, 30 Credit Suisse Securities (USA) LLC v. Billing, 551 U.S.
    [Show full text]
  • Complaint, “Chronic Pain” Means Non-Cancer Pain Lasting Three Months Or Longer
    TABLE OF CONTENTS Page I. INTRODUCTION ...............................................................................................................1 II. JURISDICTION AND VENUE ..........................................................................................8 III. PARTIES .............................................................................................................................8 A. Plaintiff ....................................................................................................................8 B. Defendants ...............................................................................................................9 IV. FACTUAL ALLEGATIONS ............................................................................................14 A. Defendants Used Multiple Avenues To Disseminate Their False And Deceptive Statements About Opioids. ...................................................................14 1. Defendants spread and continue to spread their false and deceptive statements through direct marketing of their branded opioids. .......................................................................................................15 2. Defendants used a diverse group of seemingly independent third parties to spread false and deceptive statements about the risks and benefits of opioids.................................................................17 a. Key Opinion Leaders (“KOLs”) ....................................................19 (1) Russell Portenoy ................................................................20
    [Show full text]
  • Non-Merger Civil Enforcement: an Overview of Recent DOJ and FTC Federal Court Litigation
    Antitrust , Vol. 32, No. 1, Fall 201 7. © 2017 by the American Bar Association. Reproduced with permission. All rights reserved. This information or any portion thereof may not be copied or disseminated in any form or by any means or stored in an electronic database or retrieval system without the express written consent of the American Bar Association. Non-Merger Civil Enforcement: An Overview of Recent DOJ and FTC Federal Court Litigation BY SONIA KUESTER PFAFFENROTH ECENT YEARS HAVE SEEN THE As a result, there are now a significant number of career attor - Department of Justice and the Federal Trade neys and economists with recent federal trial court experience, Commission appearing with regularity in fed - which they will bring to future cases at the investigative phase eral district court, with the agencies demon - with an eye towards potential litigation. strating a willingness to litigate in both the Rmerger and non-merger context and with a number of high- DOJ Litigation profile trials now in the rearview mirror. Because the DOJ has no administrative adjudicative process, While the majority of civil conduct enforcement actions its civil enforcement cases, whether they are settlements or continue to be filed concurrently with settlements—which contested litigation, are filed directly in federal district court. provide significant insight into the government’s theories— In recent years, the DOJ has litigated a number of cases alleg - both agencies have seen an uptick in the number of contest - ing Section 1 violations and one case alleging a Section 2 vio - ed cases filed in federal district court since the beginning of lation.
    [Show full text]
  • FDA Listing of Authorized Generics As of July 1, 2021
    FDA Listing of Authorized Generics as of July 1, 2021 Note: This list of authorized generic drugs (AGs) was created from a manual review of FDA’s database of annual reports submitted to the FDA since January 1, 1999 by sponsors of new drug applications (NDAs). Because the annual reports seldom indicate the date an AG initially entered the market, the column headed “Date Authorized Generic Entered Market” reflects the period covered by the annual report in which the AG was first reported. Subsequent marketing dates by the same firm or other firms are not included in this listing. As noted, in many cases FDA does not have information on whether the AG is still marketed and, if not still marketed, the date marketing ceased. Although attempts have been made to ensure that this list is as accurate as possible, given the volume of d ata reviewed and the possibility of database limitations or errors, users of this list are cautioned to independently verify the information on the list. We welcome comments on and suggested changes (e.g., additions and deletions) to the list, but the list may include only information that is included in an annual report. Please send suggested changes to the list, along with any supporting documentation to: [email protected] A B C D E F G H I J K L M N O P Q R S T U V X Y Z NDA Applicant Date Authorized Generic Proprietary Name Dosage Form Strength Name Entered the Market 1 ACANYA Gel 1.2% / 2.5% Bausch Health 07/2018 Americas, Inc.
    [Show full text]
  • November 26, 2018 Dr. Sol Barer Chairman of the Board Teva
    November 26, 2018 Dr. Sol Barer Chairman of the Board Teva Pharmaceutical Industries Limited Basel Street, P.O. Box 3190, Petach Tikva 4951033, Israel Dear Dr. Barer, We write to you as members of the Investors for Opioid Accountability (IOA) which represents a diverse global coalition of public, faith-based, labor, and sustainable funds, as well as asset managers with $2.2 trillion in assets under management.1 The IOA came together in 2017 out of concern for the potential risks that opioids present for the companies in which we invest. As global investors, we are writing to request a meeting with you to discuss potential financial, legal and reputational risks Teva Pharmaceutical Industries Limited (“Teva”) is facing related to the manufacturing and sale of opioids, and to ask that the Board consider adopting governance reforms designed to mitigate those risks. Opioid abuse is undeniably a public health crisis across North America and now spreading outside the U.S. as well. The U.S. Centers for Disease Control and Prevention (“CDC”) report that in 2016 alone, opioid abuse caused 42,249 deaths in the United States, or 115 people per day. In Canada, there were approximately 4,000 opioid-related deaths in 2017, a 34% increase from the prior year and a rate of 10.9 deaths per 100,000 people. In the UK and Wales, people dying from opioids related deaths in 2016 reached a record high of 3,700. In the U.S., the economic and social effects of the opioid crisis have been profound. Economist Alan Krueger has estimated that nearly 50% of prime age non-labor force men take prescription medication on a daily basis, with almost two-thirds of these being prescription pain medication.
    [Show full text]
  • Lilly to Acquire Imclone Systems in $6.5 Billion Transaction
    Lilly to Acquire ImClone Systems in $6.5 Billion Transaction Creates a Global Leader in Oncology Biopharmaceuticals Boosts Oncology Pipeline With Up to Three Promising Targeted Therapies in Phase III in 2009 INDIANAPOLIS and NEW YORK, Oct 06, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Eli Lilly and Company (NYSE: LLY) and ImClone Systems Inc. (Nasdaq: IMCL) today announced that the boards of directors of both companies have approved a definitive merger agreement under which Lilly will acquire ImClone through an all cash tender offer of $70.00 per share, or approximately $6.5 billion. The offer represents a premium of 51 percent to ImClone's closing stock price on July 30, 2008, the day before an acquisition offer for ImClone was made public. ImClone's board recommends that ImClone's shareholders tender their shares in the tender offer. Additionally, certain entities associated with ImClone's chairman, Carl C. Icahn, holding approximately 14 percent of ImClone's outstanding common stock, have agreed to tender their shares in the tender offer. This strategic combination will create one of the leading oncology franchises in the biopharmaceutical industry, offering both targeted therapies and oncolytic agents along with a pipeline spanning all phases of clinical development. The combined oncology portfolio will target a broader array of solid tumor types including lung, breast, ovarian, colorectal, head and neck, and pancreatic, positioning Lilly to pursue treatments of multiple cancers. Combining with ImClone will further strengthen Lilly's growing portfolio of first-in-class and best-in-class pharmaceutical products, enabling Lilly to better support oncologists, with the ultimate goal of delivering better outcomes for cancer patients.
    [Show full text]
  • 1 2 3 4 5 6 7 8 ABCDEFG First Name Last Name
    ABC D E F G Consultant, Speakers Bureau Stock or Other Financial 1 First Name Last Name Institution Grant/Research Support or Advisory Board Member Options University of Texas Southwestern Medical 2 Kenneth Altshuler MD Center Dallas Janssen Abbott, Bristol‐Myers Squibb, Eli Lilly, Forest, Janssen, AstraZeneca, Bristol‐ AstraZeneca, Pfizer, Myers Squibb. Eli Lilly, 3 Lori Altshuler MD UCLA Abbott GlaxoSmithKline, Wyeth GlaxoSmithKline Western Psychiatric Institute Shire, Schering‐Plough, Jazz, 4 Boris Birmaher MD Pittsburg, PA Forest Solvay Abbott, Bristol‐Myers Squibb, Elan, GlaxoSmithKline, Janssen, Johnson & Johnson, Abbott, GlaxoSmithKline, Lilly Research, Parke‐Davis, Janssen, Eli Lilly, Lilly Research, Abbott, AstraZeneca, Eli University of Texas Health Robert Wood Johnson and Sanofi‐Synthelabo, UCB Lilly, GlaxoSmithKline, 5 Charles Bowden MD Science Center San Antonio Smith Kline Beecham Pharma, AstraZeneca, Pfizer Janssen AstraZeneca, GlaxoSmithKline, Merck, Organon, Pfizer, Roche, 6 Robert Buchanan MD University of Maryland Janssen, Ortho‐McNeil Solvay, Wyeth Abbott, AstraZeneca, Bristol‐ Myers Squibb, Eli Lilly, Abbott, AstraZeneca, Bristol‐ Abbott, AZ, BMS, Eli Lilly, Janssen, Pfizer, Solvay, Myers Squibb, Eli Lilly, Janssen, Janssen, Pfizer, Alamo, 7 Peter Buckley MD Medical College of Georgia Novartis Merck, Pfizer, Alamo, Novartis AstraZeneca Abbott, AstraZeneca, Merck, Abbott, AstraZeneca, Bristol‐ GlaxoSmithKline, Janssen, Eli Myers Squibb/Otsuka, Eli Lilly, Lilly, Pfizer, Ciba‐Geigy, GlaxoSmithKline, Janssen, Robert Wood
    [Show full text]
  • 11/09/2016 Provider Subsystem Healthcare and Family Services Run Time: 20:25:21 Report Id 2794D051 Page: 01
    MEDICAID SYSTEM (MMIS) ILLINOIS DEPARTMENT OF RUN DATE: 11/09/2016 PROVIDER SUBSYSTEM HEALTHCARE AND FAMILY SERVICES RUN TIME: 20:25:21 REPORT ID 2794D051 PAGE: 01 NUMERIC COMPLETE LIST OF PHARMACEUTICAL LABELERS WITH SIGNED REBATE AGREEMENTS IN EFFECT AS OF 01/01/2017 NDC NDC PREFIX LABELER NAME PREFIX LABELER NAME 00002 ELI LILLY AND COMPANY 00145 STIEFEL LABORATORIES, INC, 00003 E.R. SQUIBB & SONS, LLC. 00149 WARNER CHILCOTT PHARMACEUTICALS INC. 00004 HOFFMANN-LA ROCHE 00168 E FOUGERA AND CO. 00006 MERCK & CO., INC. 00169 NOVO NORDISK, INC. 00007 GLAXOSMITHKLINE 00172 IVAX PHARMACEUTICALS, INC. 00008 WYETH LABORATORIES 00173 GLAXOSMITHKLINE 00009 PFIZER, INC 00178 MISSION PHARMACAL COMPANY 00013 PFIZER, INC. 00182 GOLDLINE LABORATORIES, INC. 00015 MEAD JOHNSON AND COMPANY 00185 EON LABS, INC. 00023 ALLERGAN INC 00186 ASTRAZENECA LP 00024 SANOFI-AVENTIS, US LLC 00187 VALEANT PHARMACEUTICALS NORTH AMERICA 00025 PFIZER, INC. 00206 LEDERLE PIPERACILLIN 00026 BAYER HEALTHCARE LLC 00224 KONSYL PHARMACEUTICALS, INC. 00029 GLAXOSMITHKLINE 00225 B. F. ASCHER AND COMPANY, INC. 00032 SOLVAY PHARMACEUTICALS, INC. 00228 ACTAVIS ELIZABETH LLC 00037 MEDA PHARMACEUTICALS, INC. 00245 UPSHER-SMITH LABORATORIES, INC. 00039 SANOFI-AVENTIS, US LLC 00258 FOREST LABORATORIES INC 00046 AYERST LABORATORIES 00259 MERZ PHARMACEUTICALS 00049 PFIZER, INC 00264 B. BRAUN MEDICAL INC. 00051 UNIMED PHARMACEUTICALS, INC 00281 SAVAGE LABORATORIES 00052 ORGANON USA INC. 00299 GALDERMA LABORATORIES, L.P. 00053 CSL BEHRING 00300 TAP PHARMACEUTICALS INC 00054 ROXANE LABORATORIES, INC. 00310 ASTRAZENECA LP 00056 BRISTOL-MYERS SQUIBB PHARMA CO. 00327 GUARDIAN LABS DIV UNITED-GUARDIAN INC 00062 ORTHO MCNEIL PHARMACEUTICALS 00338 BAXTER HEALTHCARE CORPORATION 00064 HEALTHPOINT, LTD. 00378 MYLAN PHARMACEUTICALS, INC.
    [Show full text]
  • Oral Presentation Disclosures
    Oral Presentation Disclosures Adler, Lenard – Alcobra Pharma, APSARD/Pond Foundation, Major League Baseball, Major League Baseball Players Association, National Football League, New York University School of Medicine, Novartis Bioventures, Shire Pharmaceuticals, Sunovion, SUNY Upstate, Theravance, US Department of Veterans Affairs Cooperative Studies Program Anton, Raymond – Abbvie, Alkermes, Eli Lilly, Ethypharm, Lundbeck, Pfizer, Sunpharma Baker, Ross – Otsuka Pharmaceutical Development & Commercialization, Inc. Baldwin, David – Lundbeck Beaver, Jessica – Targacept, Inc. Bencherif, Merouane – Targacept, Inc. Bertolino, Alessandro – F. Hoffmann-La Roche, Ltd. Bradshaw, Mark – Euthymics Bioscience, Neurovance, Inc. Burdick, Katherine – Dainippon Sumitomo Pharma Bymaster, Frank – Euthymics Bioscience, Neurovance, Inc. Calabrese, Joseph – Sunovion, Teva (Cephalon) Cantillon, Marc – Forest, Kyowa, Lilly, Merck, Pfizer, Reviva Caroff, Stanley – Sunovion Chen, Yinzhong – Takeda Development Center Americas, Inc. Chengappa, Roy – Pfizer, Inc. Childress, Ann – Abbott Laboratories, Bristol Myer Squibb, GlaxoSmithKline, Ironshore, Janssen (Ortho-McNeil), Johnson & Johnson PRD, Lilly, Neos Therapeutics, Neurovance Inc., NextWave, Novartis, Noven, Otsuka, Pfizer, Rhodes, Sepracor, Shionogi, Shire, Somerset, Sunovion, Theravance Christine, Mazzucco – Janssen Cohen, Lee – Astra-Zeneca Pharmaceuticals, Bristol-Myers Squibb, Cephalon, Inc., GlaxoSmithKline, National Institute of Mental Health, National Institute on Aging, Noven Pharmaceuticals, Ortho-McNeil
    [Show full text]